EIKEN肺炎鏈球菌快速檢測試劑盒

廣州健侖生物科技有限公司

主要用途：用于檢測尿標(biāo)本中的肺炎鏈球菌抗原，以支持肺炎鏈球菌感染的診斷。

產(chǎn)品規(guī)格：20T/盒

存儲條件：2-30℃

EIKEN肺炎鏈球菌快速檢測試劑盒

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

【產(chǎn)品介紹】

EIKEN

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】

幾個主要的癌癥相關(guān)的Rb突變和功能失調(diào)，以及細(xì)胞周期蛋白D一直被描述為促進癌癥的一個致癌基因，因為它被認(rèn)為是通過一種叫做磷酸化的過程，使Rb的抑癌功能失活。
道迪和他的同事們精心計算細(xì)胞周期進程期間的磷酸鹽添加到Rb的數(shù)量。這多達14個，但科學(xué)家發(fā)現(xiàn)，細(xì)胞周期蛋白D只增加了一個單磷酸，且只有細(xì)胞周期進程的早期G1期的14個位點中的一個，基本上有14個不同亞型的Rb。單磷酸鹽的作用是激活RB，不使它失活，這個認(rèn)知已超過了20年。
研究人員說，這項研究從根本上改變了對G1期細(xì)胞周期調(diào)控和許多癌癥相關(guān)的分子起源的理解。非常重要的是要明白一個基因通路的實際功能和中斷它的后果，尤其是細(xì)胞周期蛋白D的多種藥物抑制劑用于抗原抗體癌的臨床試驗測試這種情況下。
據(jù)認(rèn)為，當(dāng)器官一旦*形成，腎細(xì)胞就不能夠繁殖了。但新的研究表明，腎臟在人類的整個生命中能夠進行再生和自我修復(fù)。
美國斯坦福大學(xué)干細(xì)胞生物學(xué)和再生醫(yī)學(xué)研究所，以及以色列賽克勒醫(yī)學(xué)院的研究人員展示了，腎臟如何不斷增長以及自我更新的驚人能力，這項發(fā)現(xiàn)抗原抗體了數(shù)十年來認(rèn)為腎臟不能夠再生的*理論，它也打開了通向修復(fù)腎臟甚至增長的新方法。
“這些基本理論對腎臟疾病和腎臟再生有直接的影響，”論文的主要作者Yuval Rinkevich博士說。這項研究發(fā)表于2014年5月15日的《Cell Reports》雜志上。
Cell Reports:腎臟的再生能力貫穿人的一生
長期以來，人們一直認(rèn)為，腎細(xì)胞在器官一旦*形成的時候就喪失了再生的能力。這項新的研究表明，腎臟在人類的整個生命中都能夠進行再生和自我修復(fù)。
“這項研究告訴我們，腎臟決不是一個靜態(tài)的器官，” 本文的高級作者、賽克勒醫(yī)學(xué)院的兒科系副教授本杰明·德克爾博士說。“令人難以置信，腎臟可以自己恢復(fù)活力，并繼續(xù)生成專門的腎細(xì)胞。”
本文的另一個高級作者是病理學(xué)和發(fā)育生物學(xué)的教授和斯坦福研究所的主任歐文·韋斯曼博士。

Several major cancer-associated Rb mutations and dysfunctions, as well as cyclin D, have long been described as an oncogene that promotes cancer as it is thought to cause the tumor suppressor function of Rb through a process called phosphorylation live.
Dodi and his colleagues carefully calculated the amount of phosphate added to the Rb during the cell cycle progression. This is up to 14, but scientists have found that cyclin D only adds one monophosphate and that only one of 14 sites in the early G1 phase of the cell cycle process has essentially 14 different subtypes of Rb. The role of monophosphates is to activate RB without inactivating it, a fact that has been recognized for more than 20 years.
The researchers said the study radically changed the understanding of the molecular origins of G1-phase cell cycle regulation and many cancers. It is very important to understand the actual function of a gene pathway and to disrupt its consequences, especially in the case of a clinical trial of multiple drug inhibitors of cyclin D for antigen-antibody cancer.
It is believed that when the organ is fully formed, the kidney cells can not reproduce. But new research shows that the kidneys are able to regenerate and repair themselves throughout human life.
Researchers at the Stem Cell Biology and Regenerative Medicine Institute at Stanford University in the United States and at the Scythian Institute of Medicine in Israel demonstrated how the kidneys are constantly growing and the amazing ability to self-renew, the antigenic antibody that for decades has not been able to regenerate the kidneys The accepted theory, it also opened up new ways to repair the kidneys and even growth.
"These basic theories have a direct impact on kidney disease and kidney regeneration," said lead author Yuval Rinkevich, PhD. The study was published in Cell Reports on May 15, 2014.
Cell Reports: The ability of the kidneys to regenerate throughout one's entire life
It has long been believed that kidney cells lose their ability to regenerate once the organ is fully formed. This new study shows that the kidneys are able to regenerate and repair themselves throughout human life.
"This study ls us that the kidney is by no means a static organ," said Benjamin Dinkel, a senior author of the article and associate professor of pediatrics at Seckler School of Medicine. "It's incredible that the kidneys can regain their own vitality and continue to produce specialized kidney cells."
Another top author of this article is a professor of pathology and developmental biology and Dr. Irving Weissman, director of the Stanford Institute.